Constipation - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.
Get a copy of this report at http://bit.ly/1QnrfgN . This is a premium report price at US$2000 for a single user PDF license
Companies Mentioned in report are AlbireoPharma, Ardelyx, Inc., Astellas Pharma Inc., Braintree Laboratories, Inc., Daiichi Sankyo Company, Limited, Dong-A Socio Group, Ironwood Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., RaQualia Pharma Inc., Rhythm Pharmaceuticals, Sanwa Kagaku Kenkyusho Co., Ltd., Shire Plc, SK Biopharmaceuticals Co., Ltd., Sucampo Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Synergy Pharmaceuticals, Inc.
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.